BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15478591)

  • 21. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of intractable nausea and vomiting.
    Wickham R
    Clin J Oncol Nurs; 2004 Feb; 8(1):91-4. PubMed ID: 14983771
    [No Abstract]   [Full Text] [Related]  

  • 23. Chemotherapy-induced nausea and vomiting.
    Rittenberg CN; Cunningham RS
    Clin J Oncol Nurs; 2005 Apr; 9(2):257-60. PubMed ID: 15853171
    [No Abstract]   [Full Text] [Related]  

  • 24. Management of chemotherapy-induced nausea and vomiting.
    Zubairi IH
    Br J Hosp Med (Lond); 2006 Aug; 67(8):410-3. PubMed ID: 16918094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and management of chemotherapy-induced nausea and vomiting.
    Moradian S; Howell D
    Int J Palliat Nurs; 2015 May; 21(5):216, 218-24. PubMed ID: 26107543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving Adherence to Evidence-Based Guidelines for Chemotherapy-Induced Nausea and Vomiting.
    Wood M; Hall L; Hockenberry M; Borinstein S
    J Pediatr Oncol Nurs; 2015; 32(4):195-200. PubMed ID: 25576315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting.
    Viale PH; Grande C; Moore S
    Clin J Oncol Nurs; 2012 Aug; 16(4):E133-41. PubMed ID: 22842698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situation.
    Van den Brande J; Brouwer A; Peeters M
    Acta Gastroenterol Belg; 2014 Jun; 77(2):240-8. PubMed ID: 25090823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
    Jordan K; Voigt W; Schmoll HJ
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Rugo HS; Aapro MS
    Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Emetogenic potential of antineoplastic agents based on clinical trials in Japan].
    Watanabe T; Handa S; Kato Y
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):335-41. PubMed ID: 25812503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Moore S; Tumeh J; Wojtanowski S; Flowers C
    Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of chemotherapy-induced nausea and vomiting.
    Van Ryckeghem F; Van Belle S
    Acta Clin Belg; 2010; 65(5):305-10. PubMed ID: 21128556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Best practice management of CINV in oncology patients.
    ;
    J Support Oncol; 2010; 8(2 Suppl 1):3-4. PubMed ID: 20629451
    [No Abstract]   [Full Text] [Related]  

  • 40. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.